The U.S. Food and Drug Administration approved Novo Nordisk’s oral semaglutide formulation for weight management, clearing the first oral GLP‑1 pill for obesity and marking a new phase in the obesity‑drug market. Regulators also granted the pill an indication to reduce major cardiovascular events, mirroring benefits of the injectable formulation. Novo Nordisk plans an early‑January commercial launch. The approval opens access for patients who prefer pills to weekly injections and shifts competitive dynamics ahead of rival oral candidates from other manufacturers.